Sugi Predict

Sugi Predict / Compounds / SCHEMBL5694313

SCHEMBL5694313

SCHEMBL5694313

O=C(O)c1ccc(O)c(-c2ccccc2)c1C(=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ ACMSD Q8TDX5 3/20 0.47
▸ HNF4A P41235 3/20 0.47
▸ ATM Q13315 2/20 0.47
▸ DHFR P00374 1/20 0.47
▸ MCL1 Q07820 1/20 0.47
▸ CDC25B P30305 1/20 0.47
▸ SRD5A2 P31213 1/20 0.47
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ KEAP1 Q14145 1/20 0.46
▸ NFE2L2 Q16236 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ CNR2 P34972 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31090355 1.00 AKR1C3 (0.48) AKR1C3ALDH1A1ACMSDHNF4AATM
SCHEMBL29945054 0.87 ACMSD (0.52) ALDH1A1ACMSDHNF4AATMDHFR
SCHEMBL28123259 0.82 MEN1 (0.53) AKR1C3ALDH1A1ATMCDC25BMEN1
SCHEMBL28492569 0.81 MEN1 (0.51) AKR1C3ALDH1A1ATMCDC25BMEN1
SCHEMBL8923912 0.80 SELL (0.55) AKR1C3ALDH1A1ACMSDHNF4ADHFR
SCHEMBL9152464 0.80 ACMSD (0.55) ALDH1A1ACMSDHNF4ADHFRMCL1
SCHEMBL6056989 0.79 AKR1C3 (0.67) AKR1C3ALDH1A1ATMCDC25BSRD5A2
SCHEMBL11026751 0.78 HNF4A (0.58) AKR1C3ALDH1A1ACMSDHNF4ADHFR
SCHEMBL4253909 0.77 CA12 (0.54) ALDH1A1ACMSDHNF4ADHFRMCL1
SCHEMBL1286775 0.77 MEN1 (0.51) AKR1C3ALDH1A1ATMCDC25BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376444-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES CYTOKINETICS INC (US) 2025-12-11 — — US claimed
US-20220298114-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES CYTOKINETICS, INC. 2022-09-22 — — US claimed
EP-3821882-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen Inc. (US) 2021-05-19 — — EP claimed
EP-2968173-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen Inc. (US) 2016-01-20 — — EP claimed
CN-105120844-A Heterocyclic compounds and uses thereof AMGEN INC 2015-12-02 — — CN claimed
US-20140309235-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES CYTOKINETICS, INC. (US) 2014-10-16 — — US claimed
WO-2014152236-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2014-09-25 — — WO claimed
US-12612366-B2 Salts and crystal forms of omecamtiv mecarbil AMGEN INC. (US) 2026-04-28 — — US disclosed
US-20250376444-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES CYTOKINETICS INC (US) 2025-12-11 — — US disclosed
US-12275704-B2 Heterocyclic compounds and their uses CYTOKINETICS, INC. (US) 2025-04-15 — — US disclosed
US-20240217933-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. 2024-07-04 — — US disclosed
US-20240199550-A1 SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL AMGEN INC. 2024-06-20 — — US disclosed
US-11926592-B2 Salts and crystal forms of omecamtiv mecarbil AMGEN INC. (US) 2024-03-12 — — US disclosed
EP-2968173-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen Inc. (US) 2016-01-20 — — EP disclosed
CN-105120844-A Heterocyclic compounds and uses thereof AMGEN INC 2015-12-02 — — CN disclosed
US-20140309235-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES CYTOKINETICS, INC. (US) 2014-10-16 — — US disclosed
WO-2014152236-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2014-09-25 — — WO disclosed
EP-1643948-A1 DIFFUSION LAYER MODULATED SOLIDS Pharmacia & Upjohn Company LLC (US) 2006-04-12 — — EP disclosed
US-20050042291-A1 Diffusion layer modulated solids HAWLEY MICHAEL (US) 2005-02-24 — — US disclosed
WO-2005004763-A1 DIFFUSION LAYER MODULATED SOLIDS PHARMACIA & UPJOHN COMPANY LLC. (US) 2005-01-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199550-A1 SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL SI, MGAM, GCG AKR1C3 2010/4885ALDH1A1 2933/4885ACMSD 171/4885
US-20140309235-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES SI, MLN, MLNR AKR1C3 1668/4885ALDH1A1 1507/4885ACMSD 52/4885
US-12275704-B2 Heterocyclic compounds and their uses SI, MLN, MLNR AKR1C3 1668/4885ALDH1A1 1507/4885ACMSD 52/4885
US-12612366-B2 Salts and crystal forms of omecamtiv mecarbil SLC28A1, SLC28A2, SLC34A1 AKR1C3 1235/4885ALDH1A1 2110/4885ACMSD 150/4885
US-20250376444-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES SI, MLN, MLNR AKR1C3 1668/4885ALDH1A1 1507/4885ACMSD 52/4885
US-11926592-B2 Salts and crystal forms of omecamtiv mecarbil SI, MGAM, GCG AKR1C3 2010/4885ALDH1A1 2933/4885ACMSD 171/4885
US-20220298114-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES SI, MLN, MLNR AKR1C3 1668/4885ALDH1A1 1507/4885ACMSD 52/4885
US-20240217933-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES SI, MLN, MLNR AKR1C3 1668/4885ALDH1A1 1507/4885ACMSD 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.